Date: 2013-04-29
Type of information:
phase: 1-2
Announcement: initiation of the trial
Company: TikoMed (Sweden)
Product: TM–400
Action
mechanism: TM–400 is a product to improve the outcome of hematopoietic stem cell transplantations (HSCT) by increasing eradication of cancer and survival.
Disease: improvement of hematopoietic stem cell transplantation for patients with hematopoietic cancer
Therapeutic area: Cancer - Oncology
Country: Sweden
Trial details:
Latest
news: * On April 29, 2013, TikoMed has initiated a phase I/II study at CTC, Sahlgrenska hospital in Gothenburg. The study documents TikoMeds orphan drug, TM-400, which can improve hematopoietic stem cell transplantation for patients with hematopoietic cancer. Studies have documented that the product has a superior profile versus current treatment and that its effects has the potential to promote cure for hematological cancers such as Multiple Myeloma and Non-Hodgkins Lymphoma. The study will document the safety and efficacy of TM-400 in healthy volunteers, is performed at CTC, Sahlgrenska hospital in Gothenburg and will be finalized in November 2013.
